Abstract
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity. Concerns regarding bumetanide as an adjunctive anticonvulsant are addressed here. An adequately powered multi-institutional trial is needed to accurately determine efficacy.
Keywords:
GABA; bumetanide; chloride; neonatal seizures.
© 2022 International League Against Epilepsy.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, N.I.H., Extramural
MeSH terms
-
Bumetanide / therapeutic use
-
Epilepsy*
-
Humans
-
Infant, Newborn
-
Infant, Newborn, Diseases*
-
Seizures / drug therapy
-
Sodium Potassium Chloride Symporter Inhibitors / therapeutic use
-
Solute Carrier Family 12, Member 2
Substances
-
Sodium Potassium Chloride Symporter Inhibitors
-
Solute Carrier Family 12, Member 2
-
Bumetanide